Treatment of Classical Hodgkin's Lymphoma Relapsed or Refractory After First-Line Therapy
Adults with classical Hodgkin lymphoma (CHL) whose disease relapses or does not respond to initial first-line treatment form a specific clinical population for whom a targeted therapeutic strategy applies.
Relapsed disease returns after a remission that followed treatment. Refractory disease has not responded to treatment at all. In both situations, classical Hodgkin lymphoma remains potentially curable.
Treatment Approach
For patients in this setting, allogeneic stem cell transplantation is among the approaches addressed in the complete protocol.
Eligibility criteria, sequencing, and the full clinical decision framework are available in the structured regimen below.
References
- Relapse means the disease comes back after a remission following treatment. Refractory means the disease has not responded to treatment.
- For patients whose disease is relapsed or refractory, HL is still potentially curable.
- Allogeneic stem cell transplantation—a procedure in which patients undergo chemotherapy and then receive stem cells from a donor.
- It is generally only done if the disease relapses after autologous transplantation.
View source ↗